Regulatory Challenges in Approval and Control of Fixed Dose Combinations (FDCs) in India

Figure 1: Classification Of Fixed Dose Combinations By Therapeutic Category

OVERVIEW OF FIXED DOSE COMBINATIONS

Definition And Concept

Fixed Dose Combinations are formulations where two or more drugs are combined in a fixed ratio.⁴ The purpose of combining medicines is to improve treatment effectiveness and patient compliance. In chronic diseases, patients are often required to take multiple medicines every day, making FDCs essential for simplifying treatment regimens.

Types And Uses Of FDCs

FDCs are classified based on therapeutic purpose.⁵ Common categories include antimicrobial combinations, cardiovascular combinations, antidiabetic combinations, respiratory combinations, and pain management combinations. In diseases like tuberculosis and HIV, combination therapy is essential to prevent drug resistance.

Figure 2: Regulatory Approval Pathway For FDCs Through CDSCO

ADVANTAGES OF FDCS

FDCs offer several key advantages in healthcare. One of the most significant is improved patient compliance — patients taking multiple medicines separately are more prone to missing doses.⁴ FDCs also reduce pill burden, particularly in chronic diseases like tuberculosis, HIV/AIDS, and diabetes where long-term treatment is required. In infectious diseases, combination products help reduce the risk of drug resistance by ensuring patients receive all required agents simultaneously.

DISADVANTAGES AND RISKS OF FDCS

Despite their benefits, FDCs also carry disadvantages.² One major problem is difficulty in dose adjustment when a patient experiences side effects from only one component. Combining multiple medicines may increase drug interactions and adverse reactions. Irrational FDCs expose patients to unnecessary drugs, increasing toxicity risk without therapeutic benefit.

REGULATORY FRAMEWORK IN INDIA

The regulation of drugs in India is governed by the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.³ The Drug Controller General of India (DCGI) plays a major role in approving new medicines. Earlier, many FDCs were approved by state authorities without central oversight, creating inconsistency and allowing irrational combinations to enter the market. Subsequent guidelines from CDSCO mandated scientific evidence, clinical data, and safety documentation for FDC approval.

CDSCO AND DRUG APPROVAL PROCESS

The CDSCO evaluates new drug applications requiring detailed information on composition, manufacturing process, stability studies, clinical data, and safety profiles.³ The approval process generally includes preclinical studies, clinical trials, bioequivalence studies, and expert committee review. The CDSCO assesses whether a combination is rational and provides therapeutic advantage compared to individual medicines used separately.

IRRATIONAL FIXED DOSE COMBINATIONS

Irrational FDCs are combinations lacking proper scientific justification.⁵ These products may contain drugs with similar mechanisms of action, unnecessary ingredients, or pharmacologically incompatible components. Examples include unnecessary antibiotic combinations, high-toxicity painkiller combinations, and cough syrups with multiple redundant ingredients. Experts have criticized the pharmaceutical industry for promoting such combinations for commercial benefit rather than patient welfare.

Figure 3: Key Regulatory Challenges in FDC Approval and Control in India

REGULATORY CHALLENGES

India faces multiple regulatory challenges in FDC approval and control.^1,5 These include lack of coordination between central and state authorities, a large volume of existing combination products requiring monitoring, limited pharmacovigilance infrastructure, and enforcement difficulties. Over-the-counter availability without prescriptions contributes to misuse. Commercial pressure from pharmaceutical companies seeking expedited approvals, combined with shortage of trained regulatory professionals, further complicates effective regulation.

BAN ON IRRATIONAL FDCS IN INDIA

In 2016, the Government of India banned more than 300 irrational FDCs following expert committee recommendations.³ Banned products included combinations used for pain relief, cough, infections, and other conditions. The pharmaceutical industry challenged the ban in court. The government maintained that many products lacked adequate scientific evidence and posed patient risks. The ban highlighted systemic weaknesses in the prior approval process and initiated further reviews and additional bans in subsequent years.

WHO GUIDELINES ON FDCS

The World Health Organization supports rational FDC use when combinations improve treatment outcomes and patient compliance.⁷ WHO recommends approval only when there is clear evidence of safety, efficacy, and therapeutic benefit, emphasizing the need for proper clinical trials, quality control, and pharmacovigilance. WHO guidance is particularly important for diseases such as tuberculosis, HIV/AIDS, and malaria where combination therapy is clinically necessary.

PHARMACOVIGILANCE AND MONITORING

Pharmacovigilance refers to post-marketing monitoring of medicine safety.⁶ India established the Pharmacovigilance Programme of India (PvPI) to collect and analyze safety data from hospitals, doctors, pharmacists, and patients. FDC monitoring is especially critical because combinations may produce unexpected interactions. Weak reporting systems and low public awareness remain significant challenges that, if addressed, could enable faster regulatory action against unsafe products.

Figure 4: Pharmacovigilance Monitoring Framework Under The Pharmacovigilance Programme Of India (PvPI)